Circulating plasma miR222‐3P status and its potential diagnostic performance in prostate cancer

Abstract

Background: Although studies suggest that miR222-3p is dysregulated in prostate cancer (PC) cells and tissues, the possible changes in the level of miR222-3p in the plasma samples of PC patients remained unclear. The present study aimed to evaluate the diagnostic value of the plasma miR222-3p expression level as a potential biomarker in PC, benign prostatic hyperplasia (BPH) and healthy people.Methods: Blood samples were collected from 100 adult males (54 patients with PC, 27 patients with BPH and 19 healthy individuals) referred to our affiliated hospital.The expression level of miR222-3p was evaluated using a quantitative reverse transcription-polymerase chain reaction. Receiver operating characteristic curves were used to evaluate miR222-3p diagnostic accuracy for discriminating between the PC, BPH and healthy individuals.Results: The expression level of miR222-3p was significantly higher in PC patients compared to healthy individuals as a fold change of 5.3 (p = 0.009), but not for BPH individuals. The diagnostic value of the plasma miR222-3p for discrimination of the PC patients from healthy individuals was reasonable [cut-off value (fold change relative to miR16-5p) = 1.69, area under the curve = 0.73, sensitivity = 0.75 and specificity = 0.74].Conclusions: Circulating plasma miR-222-3p significantly upregulated in PC patients, but not in BPH ones. Besides these preliminary results showed that miR222-3p has the potential to discriminate PC patients from healthy ones. Addittional studies with a larger sample size are required to confirm these data.

Preliminary study on miRNA in prostate cancer

“…The results of the present study are consistent with them, and patients with low miRNA-222 expression levels were more likely to develop prostate cancer than those with high miRNA-222 expression levels. Zohreh Heydari et al [ 49 ] found in their latest study that miRNA-222 was significantly upregulated in the circulating plasma of prostate cancer patients, but not significantly upregulated in prostate hyperplasia patients. The results of our study are the opposite, possibly because prostate biopsy may affect the expression of miRNA in the peripheral blood circulation.…”

Role of Increased miR-222-3p Expression in Peripheral Blood and Wound Marginal Tissues of Type 2 Diabetes Mellitus Patients with Diabetic Foot Ulcer

“…The miR-222-3p expression in PB is capable of predicting the MPP diagnosis and prognosis from biological perspective, and also serves for prostate cancer detection as a biomarker without invasiveness. 37,38 In this study, based on ROC curve analysis results, miR-222-3p expression in T2DM patients' PB could predict DFU risk as a useful biomarker. In addition, miR-222-3p expression in PB and WMT showed a positive relevance to DFU duration, complete healing time of DFU and a negative relevance to the wound healing rate after eight weeks of treatment.…”